Eli Lilly has returned to Nimbus Therapeutics for another metabolic collaboration, this time focused on the red-hot R&D space ...

Nimbus and Eli Lilly collaborate to develop an oral treatment for obesity, leveraging computational chemistry and structure-based drug design. Nimbus Therapeutics and Eli Lilly announce their ...

An international research team reveals new molecular mechanisms associated with pathogenic mutations in the protein ...

Eli Lilly (LLY) stock is in focus as Nimbus Therapeutics expands its research deal to develop an oral obesity drug in a deal ...

Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

MIT researchers are now turning the prolific Boltz series of models into a software company that promotes open science for AI-guided therapeutics.

Join us for a webinar on how advances in target-based drug discovery are reshaping therapeutic design. We’ll explore ...

Using a blend of computer modeling, structural and cell-based studies, scientists at The Wertheim UF Scripps Institute have ...

The Singapore-based AI clinical trial engine powering Asia’s—especially China’s—rapid rise in the biotech industry. Deep ...

Nimbus Therapeutics on Tuesday said that it has entered into a multi-year agreement with drugmaker Eli Lilly & Co to develop ...

An international research team reveals new molecular mechanisms associated with pathogenic mutations in the protein transthyretin that cause ...